Suzetrigine

A non-opioid pain medicine that blocks NaV1.8 sodium channels, FDA-approved for moderate to severe acute pain in adults.

psilodex.org/m/suzetrigine · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~24 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Suzetrigine”, v2026.10.05. psilodex.org/m/suzetrigine

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Moderate to severe acute pain in adults

Sources [1]

Other safety

The label contraindicates strong CYP3A inhibitors and notes reduced effect of some hormonal contraceptives (other than levonorgestrel and norethindrone).

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; it speeds up an enzyme that helps clear psilocybin, so slightly lower levels are possible.

Detail There are no psilocybin data for suzetrigine. Its label describes it as a peripheral NaV1.8 pain-signal blocker and a CYP3A inducer (it speeds up a liver enzyme). CYP3A4 metabolized psilocin (psilocybin's active form) in lab studies (Thomann 2024). So induction may slightly lower psilocin levels, though psilocin is eliminated mainly by glucuronidation and conversion to 4-HIAA. Separately, strong CYP3A inhibitors are contraindicated with it. Sources [1][2]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~24 h (effective) (FDA label, checked 2026-10-04) Active metabolite M6-SUZ ~33 h.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Speeds up drug metabolism: Increases the liver enzymes that break down many medicines, lowering their levels. When it is stopped, levels of other medicines can rise over the following weeks. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

JOURNAVX (suzetrigine) tablets (Vertex) · FDA label (DailyMed) — Speeds up drug metabolism: 5.2 "Suzetrigine is an inducer of CYP3A." | 12.1 "By selectively inhibiting NaV1.8 channels, suzetrigine inhibits transmission of pain signals to the spinal cord and brain." | 12.3 Table "Mean (CV%) Effective Half-Life, hours 23.6 (36.2%)"
Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — Abstract: "recombinant CYP2D6 and CYP3A4 enzymes metabolized nearly 100% and 40% of psilocin, respectively." "MAO-A transformed psilocin into minimal amounts of 4-HIAA and 4-HTP." "In conclusion, MAO-A, CYP2D6, and CYP3A4 are involved in psilocin's metabolism." Introduction: "Around 33% of a psilocybin dose is renally excreted as 4-HIAA."

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →